Posted by Michael Wonder on 20 Jan 2022
Statement on the arrival of the Novavax vaccine and COVID-19 pills
20 January 2022 - Medicines Australia welcomes the TGA’s provisional approval for the Novavax COVID-19 vaccine and the provisional approval for two medicines for the symptoms of COVID-19 (Pfizer’s ‘Paxlovid’ and Merck Sharp & Dohme’s ‘Lagevrio’).
“The Novavax vaccine, called ‘Nuvaxovid’, has now passed the TGA’s rigorous assessment and approval processes. Adding this vaccine to our arsenal is another step forward for Australia as we continue to combat the COVID-19 pandemic,” said CEO of Medicines Australia, Elizabeth de Somer.
The Novavax vaccine is the first protein COVID-19 vaccine to be approved in Australia, but the technology has been around for decades. Vaccines to prevent hepatitis B and human papillomavirus infection are both based on similar protein technology.
